Open AccessComparative efficacy of dabrafenib + trametinib versus treatment options for metastatic melanoma in first-line settings
Author(s) -
Jing Wu,
Jaydeep Das,
Manik Kalra,
Barbara Ratto
Publication year - 2021
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2020-0249
Subject(s) - dabrafenib , trametinib , medicine , vemurafenib , oncology , metastatic melanoma , melanoma , overall survival , randomized controlled trial , progression free survival , clinical trial , mapk/erk pathway , cancer research , kinase , biology , microbiology and biotechnology
Aim: The objective was to systematically review the literature and assess the relative efficacy of agents approved in first-line settings via network meta-analysis. Materials & methods: A literature review was conducted via searching different medical databases. The eligibility criteria included Phase II or III randomized controlled trials that had enrolled treatment-naive adult patients with advanced/metastatic melanoma. Results: The network meta-analysis results suggested that dabrafenib + trametinib significantly prolongs the survival outcomes compared with the monotherapies and had comparable efficacy profile compared with encorafenib + binimetinib and cobimetinib + vemurafenib. In comparison with immunotherapies, the results varied for progression-free survival and overall survival. Conclusion: Long-term survival data of dabrafenib + trametinib establishes the combination as one of the preferred treatment options for previously untreated melanoma patients.